JL Yang, JX Han, ZM Shen, LJ Lu, CH Xu, HL Zhang, DE Wang , SH Xu, . IN VIVO AND IN VITRO ANTITUMOR ACTIVITIES OF ACLACINOMYCIN A MADE IN CHINAJ. Acta Pharmaceutica Sinica, 1988, 23(5): 321-326.
Citation: JL Yang, JX Han, ZM Shen, LJ Lu, CH Xu, HL Zhang, DE Wang , SH Xu, . IN VIVO AND IN VITRO ANTITUMOR ACTIVITIES OF ACLACINOMYCIN A MADE IN CHINAJ. Acta Pharmaceutica Sinica, 1988, 23(5): 321-326.

IN VIVO AND IN VITRO ANTITUMOR ACTIVITIES OF ACLACINOMYCIN A MADE IN CHINA

  • Aclacinomycin A (aclarubicin; ACM-A), an anthracycline antibiotic, is produced by the culture of Streptomyces galileus isolated from a soil specimen collected in Shanghai.Experiments demonstrated that ACM-A exhibited a significant cytotoxicity against murine leukemia P388 and human stomach carcinoma cells (SGC-7901) in vitro. ACM-A was shown to suppress the clonal growth of P388 stem cells with an ID50 of approximately 0.0085 μg/mh In transplantable tumor system, ACM-A 1.25~3.0 mg/kg ip prolonged the life-span of mice bearing P388 leukemia or Ehrlich carcinoma, and cured mice bearing P388 leukemia by 56.3%. ACM-A also inhibited the growth of solid sarcoma-180 in mice. ACM-A exerted the same degree of inhibitory action on 3H-TdR incorporation into DNA as adriamycin and less than daunomycin in cultured P388 cells. It also inhibited 3H-uridine and 3H-leucine incorporation into RNA and protein, respectively. The ip acute LD50 of ACM-A was found to be 32.1 mg/kg in BDF1 mice.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return